The current study built on the previous work as it analyzed the cumulative impact of TBS (i.e., metric of tumor morphology) and serum AFP levels (i.e., metric of tumor aggressiveness) among patients with resectable HCC. The gene discussed is AFP; the disease is neoplasm.